Insights into Pneumocystis jirovecii pneumonia in South Africa (2018-2022).

Pneumocystis jirovecii causes P. jirovecii pneumonia (PJP)-a leading opportunistic infection among persons with advanced human immunodeficiency virus. Furthermore, individuals with underlying conditions such as cancer and transplant recipients are susceptible to PJP. Most data on PJP come from other countries, with limited knowledge about its prevalence in Africa. The aim was to describe changes in the proportion of positive PJP tests in South Africa from 2018 to 2022. A 5-year retrospective study was conducted on patients with suspected P. jirovecii, detected by polymerase chain reaction. Data were obtained from the National Health Laboratory Service, where laboratory diagnostics were done as part of routine patient care. Mann-Whitney test and Χ2 tests were used to compare the age, sex, and wards with both the negative and positive results of PJP. From 2018 to 2022, a total of 8110 patients' results were retrieved, and 8059 met the inclusion criteria. The positive test proportions of PJP in South Africa were 32.66%, 29.93%, 34.02%, 24.98%, and 25.78%, respectively. The median age was 35 years, with interquartile range of 24-43 years (P = .002). Female patients had a higher positive test proportion than males (59.39% vs. 38.74%, P < .001). The proportion of positive PJP tests was higher in general wards (48.54%) and intensive care units (18.99%) (P = .012). The epidemiology of PJP in South Africa is similar to that of other countries in some respects but is influenced by unique factors specific to the country. These findings are crucial for public health planning, emphasising the need for targeted PJP prevention strategies considering sex- and age-specific vulnerabilities in South Africa.